Alto Neuroscience (ANRO) Total Current Liabilities (2023 - 2026)

Alto Neuroscience has reported Total Current Liabilities for 4 years, with the latest figure at $13.1 million in Q1 2026.

• Quarterly Total Current Liabilities rose 80.72% year-over-year to $13.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.1 million (up 80.72% YoY) and the FY2025 annual result came in at $11.3 million, up 13.16% from the prior year.
• Total Current Liabilities grew to $13.1 million in Q1 2026 per ANRO's latest filing, from $11.3 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $14.0 million in Q3 2024 and troughed at $5.6 million in Q4 2023.
• A 4-year average of $9.6 million and a median of $9.4 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2025 and 2026: Total Current Liabilities sank 35.46% in 2025, then soared 80.72% in 2026.
• Over 4 years, Total Current Liabilities stood at $5.6 million in 2023, then jumped by 78.4% to $10.0 million in 2024, then grew by 13.16% to $11.3 million in 2025, then rose by 15.81% to $13.1 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $13.1 million, $11.3 million, and $9.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.